Summary

The monoclonal antibody evolocumab (previously AMG 145), which inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), dramatically lowered levels of low-density lipoprotein cholesterol (LDL-C) in Phase 2 clinical trials when administered alone or in combination with a statin, including among patients intolerant of statin therapy, those with familial hypercholesterolemia, and in those treated in a 52-week study [Koren MJ et al. Circulation 2013; Giugliano RP et al. Lancet 2012; Koren MJ et al. Lancet 2012; Raal F et al. Circulation 2012; Sullivan D et al. JAMA 2012]. This article discusses the Phase 3 LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2 study [LAPLACE-2; NCT01763866].